.png){kind=icon}
返回
Reverse Selection Designs for Accommodating Multiple Control Arms
.png){kind=icon}
PRE
AI
DOI：10.1158/1078-0432.CCR-24-1282.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Evaluating a novel treatment in a randomized controlled trial requires comparison against existing therapies. If several existing therapies of similar benefit exist, the identification of a single control regimen may be difficult. For this situation, we propose a reverse selection design which, in its simplest form, includes a single experimental treatment arm and two control arms. Rather than carrying both control arms through the entire trial, the control arms are compared at an early interim analysis, ideally while accrual is ongoing. At this time, the worst-performing control arm is dropped and randomization continues to the remaining arms. At the end of the study, we compare the treatment to the remaining control arm. When no head-to-head comparison of the extant therapies is available or feasible, this design requires a smaller sample size than a traditional three-arm design or two sequential trials in which the extant therapies are compared and the better treatment is used in a subsequent trial as the control arm. This is because the final comparison is only between two arms and because the early interim analysis occurs prior to the end of accrual-yet with enough information such that any substantially better control arm will be selected. We evaluate the operating characteristics of a reverse selection design via simulation and show that it reduces the required sample size needed to compare the treatment against the best control, controls type I error, and likely selects the right control arm to use in the final analysis.
Keyword:
NIVOLUMAB
BEVACIZUMAB
IPILIMUMAB
期刊
IF:
10.2
论文数:
1.8W
被引数:
9.3W
机构
暂无机构信息
引用论文
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance黑色素瘤检查点阻断免疫治疗十年: 了解免疫敏感性和耐药性的分子基础.png)
NATURE IMMUNOLOGY
OAAI
NATURE IMMUNOLOGYIF27.6
OAAI分享收藏Retroperitoneal laparoscopic versus open pyeloplasty with a minimal incision: comparison of two surgical approachesUrology
UrologyIF0
PREAI
分享收藏Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma在切除的高风险黑色素瘤中，辅助使用Pembrolizumab与IFNα2b或IpilimumabCANCER DISCOVERYOAAI
CANCER DISCOVERYIF33.3
OAAI分享收藏分享收藏分享收藏
查看更多内容